Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray

Figures

• 

  Figure 1. Correlation of sVNT values to NT titers against D614G (WT), Delta, and Omicron BA.1, BA.2, and BA.5. (A) Each dot represents a single serum (n = 95). The x-axis shows live-virus NT titers; the y-axis shows the neutralizing activity assessed by the sVNT ACE2-Inhib. (ACE2-RBD inhibition). The cohorts are color coded as indicated. Spearman’s r is indicated in the top-left corner of each panel. The dotted lines indicate the cutoff values of the respective tests. The black line indicates the linear regression slope. (B) Neutralization profiles of vaccinated and infected cohorts. Each serum is represented by five dots (one for each variant), connected by a grey line. The bold blue lines indicate the median titer for each variant. WT infection: sera drawn from unvaccinated patients hospitalized for a wild-type SARS-CoV-2 infection (n = 18). 2 × Vacc.-monov./3 × Vacc.-monov. Sera drawn approximately one month after two (n = 11)/three vaccinations (n = 14) with a monovalent wild-type vaccine. 4 × Vacc.-biv. (BA.1/WT)/4 × Vacc.-biv. (BA.5/WT): Sera were drawn after a booster with a bivalent Omicron-adapted vaccine containing mRNA encoding for the Spike of either BA.1 and WT (n = 9) or BA.5…

• 

  Figure 2. Neutralizing activity of the vaccinated and infected cohorts. Cross-neutralizing activity was assessed by calculating the ratio of sVNT values (ACE2-Inhib.) of Delta, BA.1, BA.2, and BA.5 divided by the ACE2-Inhibition against WT, respectively. A single dot represents one serum. The median is shown as a solid line, and boxes and whiskers represent the quartiles and range, respectively. ACE2-Inhib. (ACE2-RBD Inhibition). WT infection: sera drawn from unvaccinated patients hospitalized for a wild-type infection (n = 18). 2 × Vacc.-monov./3 × Vacc.-monov. Sera drawn approximately one month after two (n = 11)/three vaccinations (n = 14) with a monovalent wild-type vaccine. 4 × Vacc.-biv. (BA.1/WT)/4 × Vacc.-biv. (BA.5/WT): Sera were drawn after a booster with a bivalent Omicron-adapted vaccine containing mRNA encoding for the Spike of either BA.1 and WT (n = 9) or BA.5 and WT (n = 13). The cohorts are color coded as in Figure 1A.